恒生生物科技指数期货上市倒计时2天！

Core Viewpoint - The launch of the Hang Seng Biotechnology Index futures on November 28 will provide essential risk management tools for the highly volatile biotechnology sector in Hong Kong, which is influenced by uncertainties in clinical trial results and regulatory approvals [1] Group 1: Market Dynamics - The biotechnology sector is characterized by its inherent volatility due to fundamental uncertainties such as clinical trial outcomes and regulatory approvals [1] - The introduction of the Hang Seng Biotechnology Index futures will facilitate better risk management for investors in this sector [1] Group 2: Valuation Challenges - Traditional valuation methods struggle to effectively assess the prospects of biotechnology companies, which are primarily driven by their research and development pipelines [1] - The futures market's price discovery function is expected to guide more reasonable value assessments for the biotechnology sector [1] Group 3: Global Market Expansion - In recent years, domestic biotechnology companies have actively expanded into global markets through intensive collaborations with large international pharmaceutical firms [1] - By 2025, approximately one-quarter of global drug licensing transactions will involve Chinese companies, indicating the growing recognition of Chinese innovative pharmaceutical firms within the global supply chain [1] - The continuous growth of the biotechnology ecosystem in the Hong Kong stock market is highlighted by these developments [1]